An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): cohort A of the OPAL trial Liu, J., Gaillard, S., Hendrickson, A., Moroney, J., Yeku, O., Diver, E., Gunderson, C., Arend, R., Ratner, E., Samnotra, V., Gupta, D., Evilevitch, L., Wang, S., Wang, P., Tang, J., Bacque, E., Liu, X., Konecny, G. ACADEMIC PRESS INC ELSEVIER SCIENCE. 2021: S17-S18

View details for Web of Science ID 000687070800026